RE:Low Oxygen EnvironmentsWorth repeating...
RawDawg101 wrote: The ability for the PDC technology to be effective in low oxygen environments is considered to be an essential factor in the recurrence and progression of non-muscle invasive bladder cancer. This form of disease represents up to 75% of newly diagnosed bladder cancer cases accounting for more than 386,000 cases and 150,000 deaths annually worldwide," said Dr. Arkady Mandel, Chief Scientific Officer of Theralase Inc. Dr. Mandel continued: "The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia and commonly presents in solid cancers, such as brain, bladder, breast, lung and prostate. Hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiotherapy), and thus very difficult to destroy. Tumor hypoxia is known to play a role in cancer metastasis (spread) and resistance to therapy, as well as the ability of cancer cells to escape destruction by the immune system. The evidence supporting the Theralase PDC technology represents a potential solution for hypoxic cancers. In our work, we described a family of Theralase PDCs that have shown an ability to switch their photoreactivity from a Type II reaction (oxygen dependent) to a Type I (free radical mediated) reaction. This is strategic to the Company in that a Type I reaction is unique and opens the opportunity of using the PDCs beyond sterilization and the treatment of superficial cancerous lesions to the treatment of harder to treat tumours".